Jacob M. Sadler

Jacob M. Sadler

Auto-generated profile, based on publicly available information

Jacob M. Sadler

Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
SCSean V Connelly
Sean V Connelly
JMJulia G Muller
Julia G Muller
MAMohamed Ali
Mohamed Ali
BNBilly E Ngasala
Billy E Ngasala
WHWahida Hassan
Wahida Hassan
JJJonathan J Juliano
Jonathan J Juliano
Artemisinin partial resistance, driven by Plasmodium falciparum K13 mutations, threatens malaria control. Zanzibar is vulnerable to artemisinin partial resistance spread but lacks recent molecular surveillance. We sequenced samples in Zanzibar and mainland Tanzania collected from 2022 to 2024. K13 mutations were found in 2 of 1440 participants (P441L, A675V) in Zanzibar and 6 of 3762 (R561H, P441L) in mainland Tanzania. Based on whole genome sequencing data, K13 mutations appear to be of African origin with regional spread. Frequent parasite importation appears to maintain partner drug mutation frequencies similar to the mainland, where artemether-lumefantrine selects for mutations favoring artesunate-amodiaquine sensitivity. Ongoing molecular surveillance remains essential to track these patterns.

4 October 2024 in medRxiv
Verified
Preprint
Open access
PDF file
JSJacob M. Sadler
Jacob M. Sadler
ASAlfred Simkin
Alfred Simkin
VTValery P. K. Tchuenkam
Valery P. K. Tchuenkam
IGIsabela Gerdes Gyuricza
Isabela Gerdes Gyuricza
AFAbebe A. Fola
Abebe A. Fola
JJJonathan J. Juliano
Jonathan J. Juliano
Background: Resistance to antimalarial drugs remains a major obstacle to malaria elimination. Multiplexed, targeted amplicon sequencing is being adopted for surveilling resistance and dissecting the genetics of complex malaria infections. Moreover, genotyping of parasites and detection of molecular markers drug resistance in resource-limited regions requires open-source protocols for processing samples, using accessible reagents, and rapid methods for processing numerous samples including pooled sequencing. Methods: P lasmodium falciparum S treamlined M ultiplex A ntimalarial R esistance and R elatedness T esting ( Pf -SMARRT) is a PCR-based amplicon panel consisting of 15 amplicons targeting antimalarial resistance mutations and 9 amplicons targeting hypervariable regions. This assay uses oligonucleotide primers in two pools and a non-proprietary library and barcoding approach. Results: We evaluated Pf -SMARRT using control mocked dried blood spots (DBS) at varying levels of parasitemia and a mixture of 3D7 and Dd2 strains at known frequencies, showing the ability to genotype at low parasite density and recall within-sample allele frequencies. We then piloted Pf -SMARRT to genotype 100 parasite isolates collected from uncomplicated malaria cases at three health facilities in Dschang, Western Cameroon. Antimalarial resistance genotyping showed high levels of sulfadoxine-pyrimethamine resistance mutations, including 31% prevalence of the DHPS A613S mutation. No K13 candidate or validated artemisinin partial resistance mutations were detected, but one low-level non-synonymous change was observed. Pf -SMARRT’s hypervariable targets, used to assess complexity of infections and parasite diversity and relatedness, showed similar levels and patterns compared to molecular inversion probe (MIP) sequencing. While there was strong concordance of antimalarial resistance mutations between individual samples and pools, low-frequency variants in the pooled samples were often missed. Conclusion: Overall, Pf -SMARRT is a robust tool for assessing parasite relatedness and antimalarial drug resistance markers from both individual and pooled samples. Control samples support that accurate genotyping as low as 1 parasite per microliter is routinely possible. SCOPE STATEMENT (200): Malaria remains a critical global public health problem. Antimalarial drug resistance has repeatedly undermined control and the emergence of artemisinin partial resistance in Africa is the latest major challenge. Malaria molecular surveillance (MMS) has emerged as a powerful tool to monitor molecular markers of resistance and changes in the parasite population. Streamlined methods are needed that can be readily adopted in endemic countries. We developed P lasmodium falciparum S treamlined M ultiplex A ntimalarial R esistance and R elatedness T esting ( Pf -SMARRT), a multiplex amplicon deep sequencing approach that uses easily accessible products without proprietary steps and can be sequenced on any Illumina sequencer. We validated this tool using controls, including mocked dried blood spots, and then implemented it to evaluate resistance and parasite relatedness among 100 samples from Cameroon. The assay was able to reliably assess the within-sample allele frequency of antimalarial resistance markers and discriminate strains within and between individuals. We also evaluated a more cost-effective surveillance approach for antimalarial resistance polymorphisms using pooled samples. While within-pool frequencies of mutations were accurate in pools with higher numbers of samples, this resulted in the loss of the ability to detect variants uncommon in the pool. Overall Pf- SMARRT provides a new protocol for conducting MMS that is easily implementable in Africa.

23 March 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SCSean V. Connelly
Sean V. Connelly
JMJulia G. Muller
Julia G. Muller
MAMohamed Ali
Mohamed Ali
BNBilly Ngasala
Billy Ngasala
WHWahida Hassan
Wahida Hassan
JJJonathan J. Juliano
Jonathan J. Juliano
Artemisinin partial resistance (ART-R), driven by Plasmodium falciparum K13 mutations, threatens malaria control. Zanzibar is vulnerable to ART-R spread but lacks recent molecular surveillance. We sequenced samples in Zanzibar and mainland Tanzania collected in 2022-2024. K13 mutations (P441L, A675V) were found in 2/1440 Zanzibar participants and 6/3762 (R561H, P441L) in mainland Tanzania. K13 mutations appear to be of African origin and spreading regionally based on whole genome sequencing data. Frequent parasite importation appears to maintain partner drug mutation frequencies similar to the mainland, where artemether-lumefantrine selects for mutations favoring artesunate-amodiaquine sensitivity. Ongoing molecular surveillance remains essential to track these patterns. Summary K13 mutations linked to artemisinin resistance were uncommon in Zanzibar and mainland Tanzania in 2022–2024. Whole genome sequencing suggests an African origin with regional spread of mutations. Continued surveillance is critical to monitor evolving resistance and drug selection dynamics.

3 December 2025 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
JJJonathan J. Juliano
Jonathan J. Juliano
CMCecile P. G. Meier-Scherling
Cecile P. G. Meier-Scherling
NYNeeva Wernsman Young
Neeva Wernsman Young
GTGeorge A. Tollefson
George A. Tollefson
SCSean V. Connelly
Sean V. Connelly
JBJeffrey A. Bailey
Jeffrey A. Bailey
: The coronavirus disease 2019 pandemic showcased the power of genomic surveillance in tracking infectious diseases, driving rapid public health responses, and global collaboration. This same infrastructure is being leveraged for malaria molecular surveillance (MMS) in Africa to address challenges such as artemisinin partial resistance and deletions in the Plasmodium falciparum histidine-rich protein 2 and 3 genes. However, variability in reporting sequencing methods and data reporting currently limits the validation, comparability, and reuse of data. To maximize the impact of MMS, minimal and optimal data that are key for validation and maximizing transparency and findable, accessible, interoperable, and reusable principles are proposed for reporting. Rather than focusing on specific data formats, in the current study, the authors propose what should be reported and why. Progressing to reporting individual infection-level polymorphism or microhaplotype data is central to maximizing the impact of MMS. Reporting must adhere to local regulatory practices and ensure proper data oversight and management, preventing data colonialism and preserving opportunities for data generators. With malaria’s challenges transcending borders, reporting and adopting standardized practices are essential to advancing research and strengthening global public health efforts.

6 March 2026 in Clinical Infectious Diseases
Verified
Journal Article
Open access
NMNatalie A Mackow
Natalie A Mackow
WSWanying Shao
Wanying Shao
LGLizhao Ge
Lizhao Ge
LKLauren Komarow
Lauren Komarow
JJJianping Jiang
Jianping Jiang
SDSarah Doernberg
Sarah Doernberg
Background: Ceftriaxone-resistant Escherichia coli infections are increasingly common, partially because of the emergence of E. coli sequence type 131 (ST131), including its subclade C2/H30Rx, which produce extended-spectrum β-lactamases. Methods: A prospective cohort including 14 US sites, which enrolled monomicrobial ceftriaxone-resistant and susceptible E. coli bloodstream infection (BSI) cases in a 1:1 ratio, was used to compare ST131 versus non-ST131 E. coli BSI, with specific attention to E. coli ST131 C2/H30Rx. Desirability of outcome ranking was determined at 30 days after infection onset. Results: This analysis included 282 patients with E. coli BSI; 43% (121/282) were E. coli ST131 and 23% (66/282) belonged to the C2/H30Rx subclade. Resistance to ceftriaxone was present in 79% (96/121) ST131, 86% (57/66) E. coli ST131 C2/H30Rx, and 27% (43/161) E. coli non-ST131. Compared to patients with non-ST131 E. coli BSI, patients with ST131 BSI were older (median 70 years, [Q1 62, Q3 76] years vs 65 years, [51, 74]; P = .005) and more often admitted from long-term care facilities (21/121 [17%] vs 7/161 [4%], P < .001). Overall and empiric carbapenem use was more frequent in the treatment of patients with ST131 BSI compared with non-ST131 BSI (overall 89/121 [74%] vs 50/161 [31%]; empiric: 58/121 [48%] vs 31/161 [19%], P < .001). Desirability of outcome ranking outcomes were similar between groups. Conclusions: Most ceftriaxone-resistant E. coli from US patients with E. coli BSI belong to ST131, particularly E. coli ST131 C2/H30Rx, serving as an important driver of carbapenem use.

28 April 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SWSamuel J. White
Samuel J. White
VTValery P. K. Tchuenkam
Valery P. K. Tchuenkam
MMMariama Mbouh
Mariama Mbouh
CGClaudia Gaither
Claudia Gaither
ABAline Gaelle Bouopda-Tuedom
Aline Gaelle Bouopda-Tuedom
IAInnocent Ali
Innocent Ali
Despite global malaria control efforts, the disease caused 263 million cases and 597,000 deaths in 2023. While Plasmodium falciparum accounts for most cases in Africa, non-falciparum species, such as P. ovale spp. and P. vivax , can cause relapse infections and are increasingly recognized as significant contributors to human disease. In particular, the highlands of West Cameroon have previously been reported to have high P. vivax infection rates. This study presents preliminary results from the Relapsing Malaria in Africa (ReMA) study, conducted in Dschang, Cameroon, to assess the prevalence and epidemiology of P. vivax and P. ovale . A cross-sectional survey of 3,661 participants from 871 households across seven health areas identified a low prevalence of P. vivax (0.1%) and P. ovale spp. (0.64%) using quantitative real time PCR (qPCR), while P. falciparum remained prevalent at 8.1%. Co-infections of P. ovale spp. with P. falciparum were observed in 23.1% of P. ovale spp. cases. While gametocytemia was common among falciparum infections, leveraging a new ovale gametocyte assay, we found that gametocytemia was uncommon among the qPCR-positive ovale infections. Spatial analysis found P. vivax and P. ovale spp. infections concentrated in Penka-Michel and Baleveng, the former having higher Anopheles spp. abundance than other areas assessed. Risk factor analysis revealed children and those with recent domestic travel had higher odds of P. falciparum infection, but no significant associations were found for P. ovale spp. infections. Entomological surveys confirmed high densities of Anopheles gambiae sensu lato ( s.l. ) and An. funestus (s.l.), with significantly higher human landing capture rates for An. gambiae s.l compared to other mosquito species. While these findings suggest that the relapsing malarias are not as widespread as previously thought in West Cameroon, understanding factors driving their persistent transmission, especially without prevalent gametocytemia, will be important for disease control. AUTHOR SUMMARY: Malaria caused 263 million cases and 597,000 deaths in 2023, with most cases in Africa due to Plasmodium falciparum . However, the dangers of other species like P. ovale and P. vivax , which can cause relapsing infections, are becoming more clear in Africa. The Relapsing Malaria in Africa (ReMA) study in Dschang, Cameroon, surveyed 3,661 people from 871 households to better understand these infections. Results showed low rates of P. vivax (0.1%) and P. ovale (0.64%) compared to P. falciparum (8.1%). Infections were more common in areas with high mosquito abundance and biting activity. While the relapsing malarias were less common than expected, understanding factors driving their persistent transmission, especially without prevalent gametocytemia, will be important for disease control.